American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM–III). Washington, DC: APA.
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM–III–R). Washington DC: APA.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). Washington, DC: APA.
Baldwin, D., Bobes, J., Stein, D. J.
et al (1999) Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. British Journal of Psychiatry, 175, 120–126.
Barlow, D. H., Gorman, J. M., Shear, M. K.
et al (2000) Cognitive-behavioural therapy, impramine, or their combination for panic disorder. The Journal of the American Medical Association, 283, 2529–2536.
British Medical Association & Royal Pharmaceutical Society of Greta Britain (2000) British National Formulary. London & Wallingford: BMJ Books & Pharmaceutical Press.
Charney, D. S., Woods, S. W., Goodman, W. K.
et al (1986) Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. Journal of Clinical Psychiatry, 47, 580–586.
Cowen, P. J. (1997) Pharmacotherapy for anxiety disorders: drugs available. Advances in Psychiatric Treatment, 3, 66–71.
den Boer, J. A. & Westenberg, H. G. (1988) Effect of serotonin and noradrenaline uptake inhibitors in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. International Clinical Psychopharmacology, 3, 59–74.
den Boer, J. A., Bosker, F. J. & Slaap, B. R. (2000) Serotonergic drugs in the treatment of depressive and anxiety disorders. Human Psychopharmacology, 15, 315–336.
El-Khayat, R. & Baldwin, D. S. (1998) Antipsychotic drugs for non-psychotic patients: assessment of the benefit/risk ratio in generalised anxiety disorder. Journal of Psychopharmacology, 12, 323–329.
Fineberg, N. (1999) Evidence-based pharmacotherapy for obsessive–compulsive disorder. Advances in Psychiatric Treatment, 5, 357–365.
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56–62.
Kahn, R. J., McNair, D. M. & Frankenthaler, L. M. (1987) Tricyclic treatment of generalized anxiety disorder. Journal of Affective Disorders, 13, 145–151.
Kruger, M. B. & Dahl, A. A. (1999) The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. European Archives of Psychiatry and Clinical Neuroscience, 249 (suppl. 1), S19–S24.
Loerch, B., Graf-Morgenstern, M., Hautzinger, M.
et al (1999) Randomised placebo-controlled trial of moclobemide, cognitive–behavioural therapy and their combination in panic disorder with agoraphobia. British Journal of Psychiatry, 174, 205–212.
Lucrubier, Y., Bakker, A., Dunbar, G.
et al (1997) A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatrica Scandinavica, 95, 145–152.
Lydiard, R. B., Morton, W. A., Emmanuel, N. P.
et al (1993) Preliminary report: placebo-controlled, double-blind study of the clincial and metabolic effects of desipramine in panic disorder. Psychopharmacology Bulletin, 29, 183–188.
Mavissakalian, M. R. & Perel, J. M. (1999) Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Archives of General Psychiatry, 56, 821–827.
Michelson, D., Lydiard, R. B., Pollack, M. H.
et al (1998) Outcome assessment and clinical improvement in panic disorder; evidence from a randomised controlled trial of fluoxetine and placebo. American Journal of Psychiatry, 155, 1570–1577.
Michelson, D., Pollack, M., Lydiard, R. B.
et al (1999) Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. British Journal of Psychiatry, 174, 213–218.
Modigh, K., Westberg, P. & Eriksson, E. (1992) Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. Journal of Clinical Psychopharmacology, 12, 251–261.
Noyes, R., Moroz, G., Davidson, J. R. T.
et al (1997) Moclobemide and social phobia: a controlled dose-response trial. Journal of Clinical Psychopharmacology, 17, 247–254.
Nutt, D. & Bell, C. (1997) Practical pharmacotherapy for anxiety. Advances in Psychiatric Treatment, 3, 79–85.
Raskin, A., Schulterbrant, J., Reatig, N.
et al (1969) Replication of factors of psychopatholgoy in interview, word behavior, and self-report ratings of hospitalized depressives. Journal of Nervous and Mental Diseases, 148, 87–98.
Rickels, K., Downing, R., Schweizer, E.
et al (1993) Antidepressants for the treatment of generalized anxiety disorder. Archives of General Psychiatry, 50, 884–895.
Rickels, K., Pollack, M. H., Sheehan, D. V.
et al (2000) Efficacy of extended-release venlafaxine in non-depressed oupatients with generalized anxiety disorder. American Journal of Psychiatry, 157, 968–974.
Rocca, P., Fonzo, V., Scotta, M.
et al (1997) Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatrica Scandanavica, 95, 444–450.
Simpson, H. B., Schneier, F. R., Campeas, R. B.
et al (1998) Imipramine in the treatment of social phobia. Journal of Clinical Psychopharmacology, 18, 132–135.
Tiller, J. W. G., Bouwer, C. & Behnke, K. (1999) Moclobemide and fluoxetine for panic disorder. European Archives of Psychiatry and Clinical Neuroscience, 249 (suppl. 1), S7–S10.
Turner, S. (2000) Psychiatric help for survivors of torture. Advances in Psychiatric Treatment, 6, 295–303.
Tyrer, P. (1997) Pharmacotherapy for anxiety disorders: using the available drugs. Advances in Psychiatric Treatment, 3, 72–78.
Walker, J. R. & Kjernisted, K. D. (2000) Fear: the impact and treatment of social phobia. Journal of Psychopharmacology, 14 (suppl. 1), S13–S23.
World Health Organization (1992) The ICD–10 Classification of Mental and Behavioural Disorders: Clinical Description and Diagnostic Guidelines. Geneva: WHO.